Table 1.
Clinical trials with gold nanoparticles as a drug delivery system.
| Trial Number | Sponsor | Device | Drugs | Disease | Number of enrolments | Number of centers | Status | Starting year | Ending year | Refs. |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT00356980 | National Institutes of Health Clinical Center, National Cancer Institute |
CYT-6091 | rhTNF | Unspecified adult solid tumor | 60 | 2 | Completed | 2006 | 2009 | [29] |
| NCT03020017 | Northwestern University, National Cancer Institute |
NU-0129 | Bcl2L12 specific RNAi | Glioblastoma | 8 | 1 | Completed | 2017 | 2020 | [30] |
| NCT02837094 | Cardiff University | C19-A3 GNP | Proinsulin peptide | Type I diabetes | 8 | 2 | Completed and data submitted | 2016 | 2020 | [31] |
| DNA_SPN_B001_17 AYUSH, Indian∗ |
Dhanvantari Nano Ayushadi | Nano Swarna Bhasma | Swarna Bhasma | Breast cancer | 3:3 | 2 | Completed | – | – | [32] |
∗ Permission from Indian government agent AYUSH. Bcl2L12: Bcl-2-like protein 12; GNP: gold nanoparticle; rhTNF: recombinant human tumor necrosis factor alpha; RNAi: RNA interference; –: no data.